Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 3.85 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $26.218 million which beat the analyst consensus estimate of $26.160 million by 0.22 percent. This is a 191.89 percent increase over sales of $8.982 million the same period last year.